Y-Biologics (338840.KQ) is poised to enter a phase of technology value reassessment as it launches full-scale business development following data disclosure at the American Association for Cancer Research (AACR) conference, according to analysts. Expectations for corporate value appreciation are rising as the company targets trillion-won-level technology transfers after presenting data on its next-generation immuno-oncology pipeline.
Growth Research stated in a report on the 9th that "major pipeline data including AR170 and AR166 will be presented at AACR 2026, marking the full-scale launch of global business development activities." The firm added that "establishing a reference through technology transfer of proprietary pipelines could build a business model leading to follow-on deals."
The core pipeline AR170 (PD-1·VEGF·IL2v) is based on the company's self-developed PD-1 antibody "Acrixolimab," combined with VEGF targeting and IL2v. It simultaneously targets tumor microenvironment improvement and immune activation. Acrixolimab is an antibody that demonstrated higher binding affinity and durability compared to existing immuno-oncology drugs in Phase 1/2a trials.
AR166 (PD-1·LAG-3·IL2v) combines LAG-3 and IL2v with the PD-1 antibody, featuring a mechanism that further enhances immune cell activation. LAG-3 is an immune-suppressive receptor that works complementarily with PD-1, and blocking it is attracting attention as a next-generation immuno-oncology target capable of additionally restoring immune responses in PD-1 non-responder patients.
Y-Biologics plans to present AR170, AR166, and IL2v screening data at AACR 2026. AR170 will focus on demonstrating differentiation potential in overall survival compared to ivonescimab. AR166 plans to present in vitro data showing superior immune cell activation compared to IBI363.
Y-Biologics has shifted from a business model of discovering antibodies for others or transferring technology early to a structure centered on proprietary drug pipelines utilizing its Multi-AbKine platform. The new approach involves advancing the development stage of its pipelines before pursuing technology transfers or co-development.
Multi-AbKine is evaluated as capable of simultaneously achieving antibody-based targeting and immune cell activation, with differentiated efficacy expected even in cold tumors, which are immune-inactive tumors. The platform combines cytokine variants—signaling molecules that activate immune cells—with antibodies targeting multiple targets.
The company will formalize key data through this conference. It aims to complete GLP toxicology, CMC, and safety verification within the year, targeting IND approval and technology transfer in 2027. The company explained that successfully completing its first global technology transfer of a proprietary pipeline would establish a reference leading to subsequent technology transfers.
However, Multi-AbKine's complex structure combining bispecific antibodies with cytokines presents higher manufacturing and quality control (CMC) difficulty compared to conventional single antibodies, which is cited as a risk factor. How stably the company can secure production process safety and scale-up feasibility during process establishment is expected to be a variable affecting corporate value.
